Phreesia (NYSE:PHR) Rating Lowered to Buy at Wall Street Zen

Phreesia (NYSE:PHR) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Sunday.

Other equities research analysts also recently issued research reports about the stock. Mizuho set a $22.00 price objective on shares of Phreesia in a research report on Wednesday. Citigroup reduced their price target on Phreesia from $29.00 to $25.00 and set a “buy” rating for the company in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a report on Wednesday, January 28th. Royal Bank Of Canada assumed coverage on Phreesia in a research report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price objective for the company. Finally, Wells Fargo & Company assumed coverage on shares of Phreesia in a research report on Thursday, January 8th. They set an “overweight” rating and a $30.00 target price on the stock. Seventeen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Phreesia currently has an average rating of “Moderate Buy” and an average price target of $29.41.

Phreesia Trading Down 2.9%

Shares of PHR stock opened at $12.22 on Friday. The company has a market capitalization of $736.74 million, a P/E ratio of -122.19 and a beta of 0.65. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $16.40 and its two-hundred day moving average is $21.92. Phreesia has a twelve month low of $12.06 and a twelve month high of $32.76.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.11. The firm had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company’s revenue for the quarter was up 12.7% on a year-over-year basis. During the same period last year, the company earned ($0.25) earnings per share. Equities analysts forecast that Phreesia will post -1.1 EPS for the current year.

Insiders Place Their Bets

In other Phreesia news, insider David Linetsky sold 6,106 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the completion of the transaction, the insider directly owned 231,723 shares in the company, valued at approximately $3,941,608.23. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Amy Beth Vanduyn sold 2,602 shares of Phreesia stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $44,260.02. Following the transaction, the senior vice president owned 160,238 shares of the company’s stock, valued at approximately $2,725,648.38. The trade was a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 60,766 shares of company stock valued at $1,013,817. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. Federated Hermes Inc. acquired a new stake in shares of Phreesia during the 3rd quarter worth about $32,000. Asset Management One Co. Ltd. purchased a new position in shares of Phreesia during the third quarter valued at approximately $45,000. KBC Group NV boosted its position in Phreesia by 83.4% during the fourth quarter. KBC Group NV now owns 3,449 shares of the company’s stock worth $58,000 after acquiring an additional 1,568 shares during the last quarter. Garner Asset Management Corp purchased a new stake in Phreesia in the 4th quarter worth approximately $81,000. Finally, State of Alaska Department of Revenue purchased a new stake in Phreesia in the 3rd quarter worth approximately $83,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.